Clinical Significance of Systemic Immune-Inflammation Index and Pan-Immune-Inflammation Index in Patients with Metastatic Gastric Cancer
Yusuf Ilhan1, Onur Yazdan Balcik21Department of Medical Oncology, Tatvan State Hospital, Bitlis, Türkiye, 2Department of Medical Oncology, Mardin Training and Research Hospital, Mardin, Türkiye
Objectives: Simple, cheap, and effective methods in predicting the prognosis of patients with metastatic gastric cancer (mGC) are still lacking. We aim to investigate whether the systemic immune-index (SII) and pan-immune-inflammation value (PIV) have a prognostic significance in patients with mGC. Methods: Patients diagnosed with pathological confirmed mGC were included and survival outcomes were evaluated. SII and PIV were calculated with the formula platelet count x neutrophil count/lymphocyte count and platelet count x neutrophil count x monocyte count/lymphocyte count, retrospectively. Cutoff values of SII (low, <730; high, ?730) and PIV (low, <390; high, ?390) were determined according to the previous studies. Results: A total of 60 patients were included the study. The median duration of follow-up was 9.0 (range: 3.0–47) months. Median progression-free survival (PFS) was found 8.2 (95%Confidence Intervals [CI]: 4.5–11.9) months and 6.1 (95% CI: 4.5–7.6) months for SII-low and SII-high groups, retrospectively (p:0.016). Median PFS was 8.2 (95% CI: 5.1–11.3) months in the PIV-low group and 5.6 (95% CI: 4.0–7.2) months in the PIV-high group (p:0.037). Multivariate Cox regression analysis was performed and high-SII was the only independent prognostic factor affecting PFS in a patient with mGC. Conclusion: SII is a simple, cheap, and useful marker and it may be used in routine clinical practice to predict the prognosis for patients with mGC if validated with prospective studies. Keywords: Metastatic gastric cancer, Pan-immune-inflammation value, Progression-free survival, Systemic immune-index
Cite This Article
Ilhan Y, Balcik O. Clinical Significance of Systemic Immune-Inflammation Index and Pan-Immune-Inflammation Index in Patients with Metastatic Gastric Cancer. EJMI. 2023; 7(2): 146-152
Corresponding Author: Yusuf Ilhan